New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2014
06:41 EDTAKERAkers Biosciences signs distribution agreement for infectious disease tests
Akers Biosciences announces a distribution agreement with Thirty Six Strategies General Trading, for the sale of the Company's PIFA PLUSS Infectious Disease Rapid Assay product line and Tri-Cholesterol "Check". The three year exclusive agreement is subject to performance minimum purchase requirements. 36S is permitted to market the Company's products in Australia, Singapore, the United Arab Emirates and Oman. Under the terms of the distribution agreement 36S is expected to immediately begin marketing the company's tests to a large and varied customer base including hospitals, paramedic and emergency services, non-governmental organizations and military forces. 36S will focus on distribution of the company's rapid HIV, Hepatitis B, Malaria and Dengue Fever tests; as well as its rapid cholesterol test, Tri-Cholesterol "Check".
News For AKER From The Last 14 Days
Check below for free stories on AKER the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
05:33 EDTAKERAkers Biosciences signs feasibility study deal with Konica Minolta
Akers Biosciences (AKER) has signed a feasibility study deal with Konica Minolta, Inc. (KNCAY) to develop a rapid test for the early detection of cardiac muscle tissue damage a condition commonly observed in patients suffering myocardial infarction. Heart attacks are the leading cause of death in U.S., with approximately 1.1M Americans suffering heart attacks each year. Konica Minolta, has asked Akers to study a diagnostic test based on Akers' proprietary Particle Immuno Filtration Assay, or PIFA, technology which, if successful, will facilitate the rapid detection of biomarkers present in a blood sample which can be used to identify cardiac muscle tissue damage. Such tissue damage can occur even at the early stages of a heart attack so early diagnosis could have a significant beneficial impact on patient treatment. The PIFA technology, when combined with Akers' proprietary Rapid Blood Cell Separation Technology, seraSTAT, permits the testing of whole blood from a finger prick sample allowing a test to be carried out in minutes at the point of care. Currently available tests for cardiac muscle tissue damage require a blood draw and the use of an interpretation device; and typically take 20-30 minutes to complete in a laboratory. Konica Minolta, at its own cost, has asked Akers to study a test which can be performed in under 10 minutes, using only a small blood sample obtained from a finger stick; and which can be read visually at the point of care.
July 17, 2014
05:47 EDTAKERAkers announces U.S. patent granted for Breath Ketone detection device
Subscribe for More Information
July 16, 2014
07:23 EDTAKERRedChip Companies to hold a virtual conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use